Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 164)
eröffnet am 31.08.08 11:55:05 von
neuester Beitrag 10.08.23 11:06:43 von
neuester Beitrag 10.08.23 11:06:43 von
Beiträge: 4.229
ID: 1.143.896
ID: 1.143.896
Aufrufe heute: 7
Gesamt: 285.538
Gesamt: 285.538
Aktive User: 0
ISIN: US84763A1088 · WKN: 164623 · Symbol: SPPI
1,0300
USD
0,00 %
0,0000 USD
Letzter Kurs 01.08.23 Nasdaq
Neuigkeiten
20.07.23 · Business Wire (engl.)  |
30.06.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 3,0000 | +42,18 | |
| 6,2500 | +24,75 | |
| 0,9600 | +18,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9300 | -17,52 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 38.374.133 von VaJo am 12.11.09 14:56:18Hi VaJo,
wollen wir das Kriegsbeil begraben, eine kleine Entschuldigung fehlt mir noch für die Dendreon Geschichte, dann ists für mich gegessen!
Die Börse findet die SPPI Zahlen noch nicht so hipp?
wollen wir das Kriegsbeil begraben, eine kleine Entschuldigung fehlt mir noch für die Dendreon Geschichte, dann ists für mich gegessen!
Die Börse findet die SPPI Zahlen noch nicht so hipp?
Vorbörslich zumindest noch keine heftige Reaktion.
Vielleicht habens die meisten noch nicht mitbekommen und warten auf Morgen.
Hat jemand die Zevalin Zahlen von Q2 auf die Kürze parat bzw. die Steigerung gegenüber Q2?
Gruß Oberländler
Vielleicht habens die meisten noch nicht mitbekommen und warten auf Morgen.
Hat jemand die Zevalin Zahlen von Q2 auf die Kürze parat bzw. die Steigerung gegenüber Q2?
Gruß Oberländler
Antwort auf Beitrag Nr.: 38.374.133 von VaJo am 12.11.09 14:56:18Und schon falsch gelesen 
4,7 Millionen ist absolut klasse
4,7 Millionen ist absolut klasse
Antwort auf Beitrag Nr.: 38.373.679 von Magnetfeldfredy am 12.11.09 14:09:55Danke Fredy,
ich sehs gerade. 7,8 M unglaublich
erstmal in Ruhe lesen....
ich sehs gerade. 7,8 M unglaublich
erstmal in Ruhe lesen....
Antwort auf Beitrag Nr.: 38.373.496 von schiedo am 12.11.09 13:50:30Hier die Details:
Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008
Approximately $7.1M Total Revenues in 3Q09 vs. No Revenue in 3Q08
ZEVALIN 3Q09 Revenues Approximately $4.7M; Up 80% vs. Approximately $2.6M Recorded by Former Partner in 3Q08
ZEVALIN Revenue Stabilization Achieved in 3Q09, Ahead of Year-End Goal
Approximately $143M in Cash and Equivalents as of September 30, 2009
Press Release
Source: Spectrum Pharmaceuticals, Inc.
On 7:00 am EST, Thursday November 12, 2009
Buzz up! 0 Print
Companies:Spectrum Pharmaceuticals, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News), a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.
Related Quotes
Symbol Price Change
SPPI 5.13 0.00
{"s" : "sppi","k" : "c10,l10,p20,t10","o" : "","j" : ""} “During the quarter, we made significant progress toward stabilizing, and ultimately growing, ZEVALIN® sales revenue, even before its September 3rd approval in the first-line setting,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We believe the sales stabilization in the third quarter is a direct result of our concerted efforts to remove many of the barriers that have hindered ZEVALIN’s use in the hospital and community settings. We continue to remain optimistic about ZEVALIN’s growth prospects, as ZEVALIN has received a Category 1 recommendation from the National Comprehensive Cancer Network® Drugs and Biologic Compendium™, we have significantly expanded our sales force, ZEVALIN received a label expanding approval in September, and we have made great progress toward a streamlined reimbursement standard for this important therapeutic.”
Third Quarter Results1 Ended September 30, 2009
Consolidated revenue of $7.1 million was comprised of product sales of $5.0 million – $4.7 million from ZEVALIN and $0.3 million from FUSILEV® – and $2.1 million attributable to the amortization of the Allergan licensing fee. This compares to no similar revenue in the same period in 2008. The Company recorded a net loss of $8.4 million, or ($0.20) per share, compared to net loss of $8.8 million, or ($0.28) per share, in the third quarter of 2008. Total research and development expenses were $5.5 million, as compared to $6.0 million in the same period of 2008, a $0.5 million, or 8.3% decrease, mainly due to sharing by its partner, Allergan Inc., of apaziquone related development costs, and a reduction in costs related to other pipeline products. Selling, general and administrative expenses were $7.0 million, a $3.9 million increase, compared to the $3.1 million in the same period in 2008, attributable to the direct cost of commercialization activities of ZEVALIN and FUSILEV and related payroll costs.
Nine-Month Results1 Ended September 30, 2009
Consolidated revenue of $29.4 million was comprised of product sales of $23.0 million – $10.6 million from ZEVALIN and $12.4 million from FUSILEV – and $6.4 million attributable to the amortization of the Allergan licensing fee. This compares to $20.7 million of one-time, non-recurring revenue in the same period of 2008 from the sale of rights to certain non-core products. The Company recorded a net loss of $17.5 million, or ($0.48) per share, compared to a net loss of $6.8 million, or ($0.22) per share, in the same period of 2008. Research and development expenses were $17.5 million, as compared to $19.1 million in the same period of 2008, a $1.6 million, or 8.4% decrease, mainly due to sharing by its partner, Allergan Inc., of apaziquone related development costs, and a reduction in costs related to other pipeline products. Selling, general and administrative expenses were $22.5 million, a $13.6 million increase, compared to the $8.9 million in the same period in 2008, attributable to the commercialization of ZEVALIN and FUSILEV and related payroll costs.
Net cash used in operations in the nine month period ended September 30, 2009 was $7.1 million. The operating cash outflows are primarily attributable to higher selling, general, and administrative expenses, substantially mitigated by revenues from ZEVALIN and FUSILEV and the participation by Allergan Inc. in apaziquone related development expenses.
During the third quarter ended September 30, 2009, the Company sold 6.6 million shares of common stock for $50 million in gross proceeds. As of September 30, 2009, the Company had cash and short term investments of $143 million, compared to $106 million as of June 30, 2009. As of
Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008
Approximately $7.1M Total Revenues in 3Q09 vs. No Revenue in 3Q08
ZEVALIN 3Q09 Revenues Approximately $4.7M; Up 80% vs. Approximately $2.6M Recorded by Former Partner in 3Q08
ZEVALIN Revenue Stabilization Achieved in 3Q09, Ahead of Year-End Goal
Approximately $143M in Cash and Equivalents as of September 30, 2009
Press Release
Source: Spectrum Pharmaceuticals, Inc.
On 7:00 am EST, Thursday November 12, 2009
Buzz up! 0 Print
Companies:Spectrum Pharmaceuticals, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News), a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.
Related Quotes
Symbol Price Change
SPPI 5.13 0.00
{"s" : "sppi","k" : "c10,l10,p20,t10","o" : "","j" : ""} “During the quarter, we made significant progress toward stabilizing, and ultimately growing, ZEVALIN® sales revenue, even before its September 3rd approval in the first-line setting,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We believe the sales stabilization in the third quarter is a direct result of our concerted efforts to remove many of the barriers that have hindered ZEVALIN’s use in the hospital and community settings. We continue to remain optimistic about ZEVALIN’s growth prospects, as ZEVALIN has received a Category 1 recommendation from the National Comprehensive Cancer Network® Drugs and Biologic Compendium™, we have significantly expanded our sales force, ZEVALIN received a label expanding approval in September, and we have made great progress toward a streamlined reimbursement standard for this important therapeutic.”
Third Quarter Results1 Ended September 30, 2009
Consolidated revenue of $7.1 million was comprised of product sales of $5.0 million – $4.7 million from ZEVALIN and $0.3 million from FUSILEV® – and $2.1 million attributable to the amortization of the Allergan licensing fee. This compares to no similar revenue in the same period in 2008. The Company recorded a net loss of $8.4 million, or ($0.20) per share, compared to net loss of $8.8 million, or ($0.28) per share, in the third quarter of 2008. Total research and development expenses were $5.5 million, as compared to $6.0 million in the same period of 2008, a $0.5 million, or 8.3% decrease, mainly due to sharing by its partner, Allergan Inc., of apaziquone related development costs, and a reduction in costs related to other pipeline products. Selling, general and administrative expenses were $7.0 million, a $3.9 million increase, compared to the $3.1 million in the same period in 2008, attributable to the direct cost of commercialization activities of ZEVALIN and FUSILEV and related payroll costs.
Nine-Month Results1 Ended September 30, 2009
Consolidated revenue of $29.4 million was comprised of product sales of $23.0 million – $10.6 million from ZEVALIN and $12.4 million from FUSILEV – and $6.4 million attributable to the amortization of the Allergan licensing fee. This compares to $20.7 million of one-time, non-recurring revenue in the same period of 2008 from the sale of rights to certain non-core products. The Company recorded a net loss of $17.5 million, or ($0.48) per share, compared to a net loss of $6.8 million, or ($0.22) per share, in the same period of 2008. Research and development expenses were $17.5 million, as compared to $19.1 million in the same period of 2008, a $1.6 million, or 8.4% decrease, mainly due to sharing by its partner, Allergan Inc., of apaziquone related development costs, and a reduction in costs related to other pipeline products. Selling, general and administrative expenses were $22.5 million, a $13.6 million increase, compared to the $8.9 million in the same period in 2008, attributable to the commercialization of ZEVALIN and FUSILEV and related payroll costs.
Net cash used in operations in the nine month period ended September 30, 2009 was $7.1 million. The operating cash outflows are primarily attributable to higher selling, general, and administrative expenses, substantially mitigated by revenues from ZEVALIN and FUSILEV and the participation by Allergan Inc. in apaziquone related development expenses.
During the third quarter ended September 30, 2009, the Company sold 6.6 million shares of common stock for $50 million in gross proceeds. As of September 30, 2009, the Company had cash and short term investments of $143 million, compared to $106 million as of June 30, 2009. As of
Trading Spotlight
Umsatzsteigerung auf über 80% - neuste Meldung auf
www.finanznachrichten.de
www.finanznachrichten.de
Die 40.000 und 15.000 Stücke im Bid liegen dort wie Blei und werden nicht bedient. Mir ist nicht ganz klar was der Bieter damit bezwecken möchte?
Das nächste ASH Meeting (5.-8. Dezember) bringt uns eine Fülle an neuen Ergebnissen vorwiegend früher Studien zu Zevalin. Es gibt starke Hinweise, dass Zevalin auch in anderen CD20-positiven Lymphoma Varianten teils durchschlagenden Erfolg bringen könnte - bei keiner oder kaum zusätzlicher Toxizität.
http://ash.confex.com/ash/2009/webprogram/start.html#srch=wo…
Wehrmutstropfen: Leider ist keine der Studie eine Zulassungstudie und das Geld für diese Studien muss erst mal in die Hand genommen werden - vetraglich muss sich auch Spectrum an ausgewählten Studien beteiligen.
Allerdings habe ich Hoffnung, dass Zevalin mit all den positiven Daten in Verbindung mit den Marketingbemühungen auf mittelfristige Sicht solch eine Akzeptanz erfährt, dass es auch auf breiter Front Off-Label eingesetzt werden könnte.
http://ash.confex.com/ash/2009/webprogram/start.html#srch=wo…
Wehrmutstropfen: Leider ist keine der Studie eine Zulassungstudie und das Geld für diese Studien muss erst mal in die Hand genommen werden - vetraglich muss sich auch Spectrum an ausgewählten Studien beteiligen.
Allerdings habe ich Hoffnung, dass Zevalin mit all den positiven Daten in Verbindung mit den Marketingbemühungen auf mittelfristige Sicht solch eine Akzeptanz erfährt, dass es auch auf breiter Front Off-Label eingesetzt werden könnte.
Antwort auf Beitrag Nr.: 38.365.354 von VaJo am 11.11.09 14:23:23Und schon wieder weg....wie immer
Premarkt High in den USA $ 5.57
Durchsuchen
